2F9U
HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with a P2 norborane
2F9U の概要
| エントリーDOI | 10.2210/pdb2f9u/pdb |
| 関連するPDBエントリー | 1A1R 1JXP 1N1L 2A4G 2A4Q 2A4R |
| 分子名称 | NS3 protease/helicase', polyprotein, ZINC ION, ... (5 entities in total) |
| 機能のキーワード | hcv, hepatitis c protease, ns3 protease, ketoamide inhibitor, viral protein |
| 由来する生物種 | Hepatitis C virus 詳細 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 47861.86 |
| 構造登録者 | Venkatraman, S.,Njoroge, F.G.,Wu, W.,Girijavallabhan, V.,Prongay, A.J.,Butkiewicz, N.,Pichardo, J. (登録日: 2005-12-06, 公開日: 2006-06-06, 最終更新日: 2024-11-20) |
| 主引用文献 | Venkatraman, S.,Njoroge, F.G.,Wu, W.,Girijavallabhan, V.,Prongay, A.J.,Butkiewicz, N.,Pichardo, J. Novel Inhibitors of Hepatitis C NS3-NS4A Serine Protease Derived from 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid. Bioorg.Med.Chem.Lett., 16:1628-1632, 2006 Cited by PubMed Abstract: Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of approximately 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections. PubMed: 16413182DOI: 10.1016/j.bmcl.2005.12.046 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.6 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






